Myorisan
NDC Package 61748-303-13

11-digit billing NDC: 61748030313 · Billing unit: EA · 30 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Myorisan is ® must not be used by female patients who are or may become pregnant. Marketed by Akorn Operating Company Llc, this product is identified by NDC 61748-303 and is authorized under FDA application ANDA076485.

Identification & Billing

NDC Package Code
61748-303-13
Package Description
3 BLISTER PACK in 1 CARTON / 10 CAPSULE, LIQUID FILLED in 1 BLISTER PACK
Product Code
11-Digit Billing Format
61748030313
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Myorisan
Dosage Form
-
Usage Information
Myorisan® must not be used by female patients who are or may become pregnant. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Myorisan® in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. Birth defects which have been documented following Myorisan® exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported. Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain of the abnormalities previously noted. If pregnancy does occur during treatment of a female patient who is taking Myorisan®, Myorisan® must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Special Prescribing RequirementsBecause of Myorisan’s ®teratogenicity and to minimize fetal exposure, Myorisan® is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This REMS is called iPLEDGE®. Myorisan® must only be prescribed by prscribers who are enrolled and activated with the iPLEDGE REMS. Myorisan® must only bedispensed by a pharmacy enrolled and activated with iPLEDGE, and must only be dispensed to patients who are enrolled and meet all the requirements of iPLEDGE. (see PRECAUTIONS).

Regulatory & Marketing

Labeler Name
Akorn Operating Company Llc
FDA Application #
ANDA076485
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-26-2015
Listing Expiration
12-31-2023
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (61748-303). Click a package code to view its specific billing and regulatory data.

5000 CAPSULE, LIQUID FILLED in 1 BAG
10 BLISTER PACK in 1 CARTON / 10 CAPSULE, LIQUID FILLED in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61748-303-13 identifies a specific commercial package of 3 blister pack in 1 carton / 10 capsule, liquid filled in 1 blister pack of Myorisan, labeled by Akorn Operating Company Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Akorn Operating Company Llc on August 26, 2015. The current certification is valid through December 31, 2023.

How is this Akorn Operating Company Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61748030313. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61748-303-13
11-Digit CMS (5-4-2)
61748-0303-13

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.